KRYS
Price
$174.44
Change
-$5.85 (-3.24%)
Updated
Apr 1, 04:59 PM (EDT)
Capitalization
5.03B
40 days until earnings call
XERS
Price
$5.08
Change
-$0.41 (-7.47%)
Updated
Apr 1, 04:59 PM (EDT)
Capitalization
782.02M
35 days until earnings call
Ad is loading...

KRYS vs XERS

Header iconKRYS vs XERS Comparison
Open Charts KRYS vs XERSBanner chart's image
Krystal Biotech
Price$174.44
Change-$5.85 (-3.24%)
Volume$4.82K
Capitalization5.03B
Xeris Biopharma Holdings
Price$5.08
Change-$0.41 (-7.47%)
Volume$58.08K
Capitalization782.02M
KRYS vs XERS Comparison Chart
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. XERS commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a StrongBuy and XERS is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (KRYS: $180.30 vs. XERS: $5.49)
Brand notoriety: KRYS and XERS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 124% vs. XERS: 195%
Market capitalization -- KRYS: $5.03B vs. XERS: $782.02M
KRYS [@Biotechnology] is valued at $5.03B. XERS’s [@Biotechnology] market capitalization is $782.02M. The market cap for tickers in the [@Biotechnology] industry ranges from $302.51B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 1 FA rating(s) are green whileXERS’s FA Score has 0 green FA rating(s).

  • KRYS’s FA Score: 1 green, 4 red.
  • XERS’s FA Score: 0 green, 5 red.
According to our system of comparison, KRYS is a better buy in the long-term than XERS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 2 TA indicator(s) are bullish while XERS’s TA Score has 4 bullish TA indicator(s).

  • KRYS’s TA Score: 2 bullish, 6 bearish.
  • XERS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, XERS is a better buy in the short-term than KRYS.

Price Growth

KRYS (@Biotechnology) experienced а -7.27% price change this week, while XERS (@Biotechnology) price change was -6.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.07%. For the same industry, the average monthly price growth was -13.26%, and the average quarterly price growth was -12.25%.

Reported Earning Dates

KRYS is expected to report earnings on May 12, 2025.

XERS is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-9.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($5.03B) has a higher market cap than XERS($782M). XERS YTD gains are higher at: 61.947 vs. KRYS (15.090). KRYS has higher annual earnings (EBITDA): 110M vs. XERS (-13.99M). KRYS has more cash in the bank: 598M vs. XERS (71.6M). KRYS has less debt than XERS: KRYS (7.26M) vs XERS (271M). KRYS has higher revenues than XERS: KRYS (291M) vs XERS (203M).
KRYSXERSKRYS / XERS
Capitalization5.03B782M643%
EBITDA110M-13.99M-786%
Gain YTD15.09061.94724%
P/E Ratio58.19N/A-
Revenue291M203M143%
Total Cash598M71.6M835%
Total Debt7.26M271M3%
FUNDAMENTALS RATINGS
KRYS vs XERS: Fundamental Ratings
KRYS
XERS
OUTLOOK RATING
1..100
7884
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
1865
SMR RATING
1..100
68100
PRICE GROWTH RATING
1..100
4535
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KRYS's Valuation (79) in the Pharmaceuticals Major industry is in the same range as XERS (92). This means that KRYS’s stock grew similarly to XERS’s over the last 12 months.

KRYS's Profit vs Risk Rating (18) in the Pharmaceuticals Major industry is somewhat better than the same rating for XERS (65). This means that KRYS’s stock grew somewhat faster than XERS’s over the last 12 months.

KRYS's SMR Rating (68) in the Pharmaceuticals Major industry is in the same range as XERS (100). This means that KRYS’s stock grew similarly to XERS’s over the last 12 months.

XERS's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as KRYS (45). This means that XERS’s stock grew similarly to KRYS’s over the last 12 months.

XERS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as KRYS (100). This means that XERS’s stock grew similarly to KRYS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSXERS
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 14 days ago
76%
Bullish Trend 9 days ago
85%
Declines
ODDS (%)
Bearish Trend 6 days ago
76%
Bearish Trend 2 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Ad is loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SUVQX12.16N/A
N/A
PGIM Quant Solutions Large-Cap Val R6
NGJIX18.34N/A
N/A
Nuveen Global Real Estate Securities I
ACSRX29.01N/A
N/A
Invesco Comstock R
USCAX12.01N/A
N/A
Victory Small Cap Stock
JORSX15.55-0.05
-0.32%
JHancock Small Cap Core R6

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with IDYA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
-1.97%
IDYA - KRYS
50%
Loosely correlated
-3.93%
ACLX - KRYS
48%
Loosely correlated
-3.47%
CRNX - KRYS
47%
Loosely correlated
-3.43%
ZLDPF - KRYS
45%
Loosely correlated
-0.66%
CGON - KRYS
45%
Loosely correlated
-7.31%
More

XERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, XERS has been loosely correlated with TRDA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XERS
1D Price
Change %
XERS100%
-1.61%
TRDA - XERS
43%
Loosely correlated
-5.44%
KRYS - XERS
41%
Loosely correlated
-1.97%
ABOS - XERS
40%
Loosely correlated
-7.56%
FHTX - XERS
39%
Loosely correlated
+3.69%
ACLX - XERS
38%
Loosely correlated
-3.47%
More